Large conductance calcium-activated K channel opener
A large conductance calcium-activated K channel opener comprising as an active ingredient a nitrogen-containing 5-membered heterocyclic compound represented by the following formula (I): wherein X represents N—R 4 , O or S, R 1 and R 2 each independently represent hydrogen, halogen, carboxyl, amino, lower alkyl, lower alkoxycarbonyl, lower alkenyl, cyclo-lower alkyl, carbamoyl, aryl, heterocyclic or heterocyclic-substituted carbonyl group, R 3 represents aryl, heterocyclic or lower alkyl group, and R 4 represents hydrogen or lower alkyl group, or a pharmaceutically acceptable salt thereof.
1. A nitrogen-containing 5-membered heterocyclic compound represented by the formula (I), or a pharmaceutically acceptable salt thereof,
wherein X represents S, R 1 represents a lower alkyl group substituted by a lower alkoxycarbonyl group, R 2 represents a phenyl group substituted by two halogen atoms, and R 3 represents a 4-lower alkoxyphenyl group.
2. A nitrogen-containing 5-membered heterocyclic compound represented by the formula (I), or a pharmaceutically acceptable salt thereof,
wherein X represents S, R 1 represents a lower alkyl group containing 1 carbon atom and being substituted by a carboxyl group or lower alkoxycarbonyl group, R 2 represents a 4-chloro-3-fluoro-phenyl group, and R 3 is a 4-lower alkoxyphenyl group.
3. A method of treating pollakiuria or urinary incontinence, comprising:
administering an effective amount of a nitrogen-containing 5-membered heterocyclic compound or a pharmaceutically acceptable salt thereof according to claim 1 or claim 2 to a patient in need thereof.
4. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 or claim 2 or a pharmaceutically acceptable salt thereof in admixture with a therapeutically acceptable carrier or diluent.